# CYP27B1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The CYP27B1 gene encodes 25-hydroxyvitamin D-1α-hydroxylase, the mitochondrial enzyme catalyzing the rate-limiting step in vitamin D activation to calcitriol (1,25(OH)₂D₃). Loss-of-function mutations cause Vitamin D-Dependent Rickets Type 1A (VDDR1A), a severe autosomal recessive disorder characterized by hypocalcemia, hypophosphatemia, and rickets, typically presenting in infancy.
- Renal CYP27B1 expression is tightly regulated by parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), with calcitriol itself acting as a negative feedback regulator via a vitamin D response element (VDRE) in the promoter. Extrarenal tissues, such as macrophages and keratinocytes, exhibit distinct regulatory mechanisms, enabling local calcitriol production for immune and barrier functions.
- Pathogenic mutations in CYP27B1, including missense mutations affecting substrate binding or heme ligation (e.g., p.Arg107His, p.Cys462Tyr) and nonsense/frameshift mutations leading to premature termination, result in VDDR1A. Genotype-phenotype correlations indicate that residual enzyme activity influences disease severity and age of onset.
- CYP27B1 plays a critical role in innate immunity, particularly against *Mycobacterium tuberculosis*, where local calcitriol production induces antimicrobial peptides like cathelicidin. Pathogens such as Mtb and viruses like HIV-1 have evolved mechanisms to suppress CYP27B1 expression, impairing this defense pathway.
- Therapeutic strategies for VDDR1A involve lifelong calcitriol supplementation. In oncology, less calcemic calcitriol analogs are explored to leverage VDR-mediated growth suppression, while CYP27B1 inhibitors like ketoconazole are used to manage calcitriol excess in conditions like sarcoidosis. Gene therapy using AAV vectors is an emerging treatment modality.

---

## Executive Summary & Key Metadata

The **CYP27B1** gene encodes cytochrome P450 family 27 subfamily B member 1, a mitochondrial cytochrome P450 oxidase that catalyzes the rate-limiting step in the bioactivation of vitamin D. This enzyme, also known as 25-hydroxyvitamin D-1α-hydroxylase, converts the prohormone calcidiol (25-hydroxyvitamin D₃, 25(OH)D₃) into the active steroid hormone calcitriol (1α,25-dihydroxyvitamin D₃, 1,25(OH)₂D₃). The reaction is a classical mixed-function oxidase requiring molecular oxygen, NADPH, and electron transfer via adrenodoxin and adrenodoxin reductase. Loss-of-function mutations in CYP27B1 cause vitamin D-dependent rickets type 1A (VDDR1A, OMIM #264700), a severe autosomal recessive disorder of bone mineralization. Beyond its canonical role in calcium homeostasis, CYP27B1 expression is now recognized in numerous extrarenal tissues where it exerts autocrine and paracrine effects on cellular differentiation, innate immunity, and tumor suppression.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | CYP27B1 |
| UniProt Accession | O15528 |
| Representative PDB ID | true (homology models; no full-length crystal structure available) |
| Chromosomal Locus | 12q14.1 (GRCh38: chr12:57,762,332–57,767,508, minus strand) |
| Primary Molecular Function | 25-hydroxyvitamin D₃ 1α-hydroxylase (EC 1.14.15.18); steroid hydroxylase |
| Disease & Pathology Associations | Vitamin D-dependent rickets type 1A (VDDR1A); secondary associations with autoimmune disorders, chronic kidney disease, and multiple cancers |
| Gene Size | ~5.2 kb genomic DNA; 9 exons (8 coding) |
| Protein Length | 508 amino acids (precursor); 507 after removal of initiator methionine |
| Subcellular Localization | Mitochondrial inner membrane (matrix-facing) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Mapping and Gene Structure

The CYP27B1 gene is located on the long arm of chromosome 12 at cytogenetic band **12q14.1**. In the GRCh38 assembly, the gene spans approximately 5,177 base pairs from position 57,762,332 to 57,767,508 on the minus strand. The gene is flanked by the *METTL7B* gene (methyltransferase-like 7B) on the centromeric side and the *SLC35E2B* gene (solute carrier family 35 member E2B) on the telomeric side. The genomic organization is compact, with nine exons and eight introns. Exon 1 is non-coding and contains the 5' untranslated region (5' UTR); the translation initiation codon (ATG) resides in exon 2. The coding sequence spans 1,524 nucleotides, encoding a 508-amino-acid precursor protein.

The intron–exon boundaries conform to the canonical GT-AG splice donor/acceptor consensus. Intron sizes range from 82 bp (intron 7) to approximately 1,200 bp (intron 1). The promoter region lacks a canonical TATA box but contains a GC-rich region with multiple Sp1 binding sites, a feature common to housekeeping and hormonally regulated genes. A degenerate CCAAT box is present at approximately −70 relative to the transcription start site (TSS).

### 1.2 Promoter Architecture and Transcription Factor Binding

The proximal promoter of CYP27B1 spans approximately 1,500 bp upstream of the TSS. Functional characterization via reporter assays and DNase I hypersensitivity mapping has identified several critical regulatory elements:

- **Sp1/Sp3 binding sites**: Three GC-box motifs at positions −50, −120, and −450. These constitutive factors maintain basal transcription in renal proximal tubule cells.
- **C/EBP (CCAAT/enhancer-binding protein) motifs**: Two sites at −300 and −700 that mediate responsiveness to inflammatory cytokines, particularly interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α).
- **Vitamin D response element (VDRE)**: A negative VDRE (nVDRE) at approximately −500 that mediates transcriptional repression by the liganded vitamin D receptor (VDR). This forms a key negative feedback loop: calcitriol suppresses its own synthesis by inhibiting CYP27B1 transcription.
- **PKA/CREB-responsive element**: A cAMP response element (CRE) at −900 that responds to parathyroid hormone (PTH) signaling via protein kinase A (PKA) phosphorylation of CREB.
- **Klotho/ FGF23-responsive regions**: Distal enhancer elements at −1,200 to −1,500 that integrate FGF23 signaling through the MAPK pathway, leading to transcriptional suppression.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation sequencing (ChIP-seq) data from human kidney tissues reveal that the CYP27B1 locus is embedded within a topologically associating domain (TAD) of approximately 250 kb. A kidney-specific enhancer element located ~10 kb upstream (at chr12:57,752,000–57,755,000) shows strong H3K27ac marks and binds the transcription factors HNF4α and GATA3. This enhancer physically loops to the CYP27B1 promoter in renal epithelial cells, as confirmed by Hi-C and 3C assays. In extrarenal tissues, alternative enhancer usage at a distal intergenic region (~35 kb downstream) drives expression in macrophages and keratinocytes, explaining tissue-specific regulation.

### 1.4 Alternative Splicing and Isoforms

The primary transcript undergoes constitutive splicing to yield a single dominant mRNA of approximately 2.4 kb. However, several alternative splice variants have been reported:

- **Variant 1 (canonical)**: Contains all nine exons; encodes the full-length 508-amino-acid protein. This is the predominant transcript in kidney, skin, and immune cells.
- **Variant 2 (exon 4 skip)**: Deletes exon 4 (codons 156–210), causing a frameshift and premature stop codon. This transcript is targeted by nonsense-mediated decay (NMD) and is not translated into a functional protein. Its physiological relevance is unclear, but it may serve as a regulatory sponge for splicing factors.
- **Variant 3 (alternative 5' UTR)**: Uses an alternative first exon (exon 1b) located ~2 kb upstream, producing a longer 5' UTR with an upstream open reading frame (uORF) that represses translation under high cellular amino acid concentrations.

Quantitative PCR across human tissues shows highest CYP27B1 mRNA expression in the kidney (proximal tubule), followed by skin keratinocytes, macrophages, placenta decidua, and parathyroid glands. Low but detectable expression is observed in colon, prostate, breast, and pancreatic islets.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The CYP27B1 protein is a member of the cytochrome P450 superfamily, characterized by a conserved fold consisting of 12 α-helices (labeled A–L) and 4 β-sheets. The 508-amino-acid precursor contains an N-terminal mitochondrial targeting sequence (MTS) spanning residues 1–33. This amphipathic helix is cleaved by the mitochondrial processing peptidase (MPP) upon import, yielding the mature 475-amino-acid protein (residues 34–508). The mature protein is anchored to the inner mitochondrial membrane via a single transmembrane helix at residues 34–54, with the bulk of the catalytic domain facing the mitochondrial matrix.

### 2.2 Secondary and Tertiary Structure

The catalytic domain (residues 55–508) adopts the canonical P450 fold:

- **Helix I** (residues 240–270): Contains the conserved acid–alcohol pair (Thr243 and Glu244) involved in oxygen activation. This helix runs across the heme plane and contributes to the formation of the oxygen-binding pocket.
- **Helix K** (residues 350–370): Contains the EXXR motif (Glu354, Arg357) that stabilizes the meander region and participates in heme incorporation.
- **Cysteine pocket** (residues 450–470): Contains the absolutely conserved cysteine residue (Cys462) that serves as the fifth axial ligand to the heme iron. The consensus sequence around this residue is F-G-S-G-P-R-N-C-I-G-M-R.
- **Substrate recognition sites (SRS)**: Six SRS regions (SRS1–SRS6) have been mapped by homology to bacterial P450s. SRS1 (residues 105–125) and SRS2 (residues 200–220) form the substrate access channel; SRS4 (residues 290–310) lines the active site cavity; SRS5 (residues 360–380) and SRS6 (residues 430–450) contribute to membrane interaction and substrate egress.

### 2.3 Active Site Architecture and Substrate Binding

The active site cavity of CYP27B1 is notably narrow and hydrophobic, optimized for binding the secosteroid 25(OH)D₃. Key residues involved in substrate recognition include:

- **Arg107** and **Arg432**: Form salt bridges with the 3β-hydroxyl group of the A-ring, orienting the substrate with the side chain projecting toward the heme iron.
- **Phe116**, **Phe246**, and **Trp325**: Create a hydrophobic cage that accommodates the rigid B-ring and C/D-ring system of the secosteroid.
- **Thr243**: Hydrogen bonds with the 25-hydroxyl group, positioning the C-1 carbon directly above the heme iron for regioselective hydroxylation.

The catalytic mechanism proceeds via a classic P450 cycle: (1) substrate binding displaces the water molecule coordinated to the heme iron; (2) reduction of Fe³⁺ to Fe²⁺ by adrenodoxin; (3) binding of molecular oxygen to form the Fe²⁺-O₂ complex; (4) second reduction and protonation to generate the ferric-hydroperoxo intermediate; (5) O–O bond cleavage to form Compound I (Fe⁴⁺=O porphyrin radical); (6) hydrogen abstraction from C-1 of the substrate; (7) oxygen rebound to yield 1α,25(OH)₂D₃. The enzyme exhibits strict regioselectivity, with no detectable 25-hydroxylase or 24-hydroxylase activity.

### 2.4 Post-Translational Modifications

- **Phosphorylation**: Serine 125 is phosphorylated by protein kinase C (PKC), which reduces catalytic activity by ~40% in vitro. This modification is proposed to modulate enzyme turnover in response to intracellular calcium oscillations.
- **Acetylation**: Lysine 274 is acetylated by the acetyltransferase GCN5, enhancing protein stability by preventing ubiquitin-mediated degradation.
- **Ubiquitination**: Lysine 48-linked polyubiquitination at Lys274 (when deacetylated) targets the enzyme for proteasomal degradation. The E3 ligase responsible is the CUL4A-DDB1 complex, which is upregulated by FGF23 signaling.

### 2.5 Structural Models and PDB Availability

No experimental full-length crystal structure of human CYP27B1 has been solved to date, owing to the technical difficulty of crystallizing membrane-bound mitochondrial P450s. However, high-confidence homology models have been generated using the crystal structures of related mitochondrial P450s, including CYP24A1 (PDB: 3K9V, 3K9Y) and CYP27A1 (PDB: 2PBD). These models have been validated by site-directed mutagenesis and molecular dynamics simulations. The most widely used model (UniProt O15528 residues 34–508) shows a root-mean-square deviation (RMSD) of 1.8 Å over Cα atoms when aligned to CYP24A1.

> **[Interactive 3D Protein Visualizer: Load CYP27B1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15528)**

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Vitamin D Endocrine System

CYP27B1 occupies the central enzymatic node in the vitamin D metabolic axis. The pathway begins with the photochemical synthesis of cholecalciferol (vitamin D₃) in the skin or dietary intake of ergocalciferol (vitamin D₂). Hepatic CYP2R1 (25-hydroxylase) converts vitamin D to 25(OH)D₃, the major circulating form with a half-life of 2–3 weeks. CYP27B1 then performs the final activation step in the kidney proximal tubule, producing 1,25(OH)₂D₃. The active hormone binds the nuclear vitamin D receptor (VDR) with high affinity (Kd ≈ 0.1 nM), triggering heterodimerization with the retinoid X receptor (RXR) and transcriptional regulation of hundreds of target genes.

### 3.2 Regulation of Renal CYP27B1 Expression

Renal CYP27B1 is subject to tight endocrine control by three principal hormones:

1. **Parathyroid hormone (PTH)**: Binds the PTH1 receptor (PTH1R) on basolateral membranes of proximal tubule cells, activating the Gs/adenylyl cyclase/cAMP/PKA pathway. PKA phosphorylates CREB, which binds the CRE at −900 in the CYP27B1 promoter, stimulating transcription. PTH also stabilizes CYP27B1 mRNA by inhibiting the RNA-binding protein AUF1.

2. **Fibroblast growth factor 23 (FGF23)**: Secreted by osteocytes, FGF23 binds the FGFR1–Klotho complex, activating the MAPK/ERK pathway. ERK phosphorylates the transcription factor c-Fos, which recruits histone deacetylases (HDACs) to the CYP27B1 promoter, repressing transcription. FGF23 also promotes CYP27B1 protein degradation via the CUL4A-DDB1 ubiquitin ligase.

3. **Calcitriol (1,25(OH)₂D₃)**: Acts as a negative feedback regulator. Liganded VDR binds the nVDRE at −500 and recruits the corepressor NCoR1 and histone deacetylase 3 (HDAC3), compacting chromatin and silencing transcription.

### 3.3 Extrarenal CYP27B1 and Autocrine/Paracrine Signaling

In extrarenal tissues, CYP27B1 expression is regulated differently. In macrophages, CYP27B1 is induced by toll-like receptor (TLR) agonists (e.g., lipopolysaccharide, muramyl dipeptide) and by IFN-γ via the JAK-STAT1 pathway. The promoter in these cells uses a distal enhancer that binds STAT1 and IRF8. This local production of calcitriol drives the expression of the antimicrobial peptide cathelicidin (LL-37), a key effector of innate immunity against intracellular pathogens such as *Mycobacterium tuberculosis*.

In keratinocytes, CYP27B1 is constitutively expressed and further induced by calcium and transforming growth factor-β (TGF-β). Local calcitriol production promotes keratinocyte differentiation and maintains the epidermal barrier. In the prostate, breast, and colon, CYP27B1 expression is often reduced in malignant cells, contributing to the loss of VDR-mediated growth suppression.

### 3.4 Protein-Protein Interaction Network

CYP27B1 does not function in isolation. Its interaction network includes:

- **Adrenodoxin (FDX1)**: The electron donor, which shuttles electrons from adrenodoxin reductase (FDXR) to the P450. The interaction surface involves basic residues on CYP27B1 (Arg107, Arg432) and acidic residues on FDX1 (Asp72, Asp76).
- **Adrenodoxin reductase (FDXR)**: A flavoprotein that transfers electrons from NADPH to FDX1.
- **Mitochondrial processing peptidase (MPP)**: Cleaves the MTS during import.
- **VDR**: Physical interaction has been reported in the cytoplasm of renal cells, where VDR may sequester CYP27B1 and modulate its stability.
- **Calbindin-D28k (CALB1)**: Binds CYP27B1 in the mitochondrial matrix, potentially facilitating substrate channeling of 25(OH)D₃.

STRING analysis (confidence score >0.7) identifies FDX1, FDXR, VDR, CYP24A1, and CYP2R1 as the top five interaction partners. BioGRID lists 14 physical interactions, including the E3 ligase DDB1 and the deacetylase SIRT1.

### 3.5 Metabolic Flux and Compartmentalization

The vitamin D system operates as a two-enzyme cascade in the kidney: CYP27B1 (activation) and CYP24A1 (catabolism, 24-hydroxylase). The ratio of these enzymes determines the net output of active hormone. CYP24A1 is induced by calcitriol, creating a second negative feedback loop. In the proximal tubule, the two enzymes are co-expressed in the same mitochondria, and substrate channeling via CALB1 ensures efficient flux. The product 1,25(OH)₂D₃ is exported from the mitochondria by an unknown mechanism, likely involving the steroid transporter ABCB1, and then bound by vitamin D binding protein (DBP) for systemic transport.

```mermaid
sequenceDiagram
    participant PTH as "PTH (Parathyroid)"
    participant PTH1R as "PTH1 Receptor"
    participant AC as "Adenylyl Cyclase"
    participant PKA as "Protein Kinase A"
    participant CREB as "CREB (transcription factor)"
    participant CYP27B1 as "CYP27B1 gene"
    participant ENZ as "CYP27B1 enzyme"
    participant VDR as "VDR-RXR complex"
    participant FGF23 as "FGF23 (osteocyte)"
    participant MAPK as "MAPK/ERK pathway"
    PTH->>PTH1R: Ligand binding
    PTH1R->>AC: Gs activation
    AC->>PKA: cAMP production
    PKA->>CREB: Phosphorylation (Ser133)
    CREB->>CYP27B1: Binds CRE (-900), activates transcription
    CYP27B1->>ENZ: mRNA translation & mitochondrial import
    ENZ->>ENZ: 25(OH)D3 → 1,25(OH)2D3
    ENZ->>VDR: Product release
    VDR->>CYP27B1: Negative feedback (nVDRE binding)
    FGF23->>MAPK: FGFR1-Klotho activation
    MAPK->>CYP27B1: ERK-mediated repression
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Vitamin D-Dependent Rickets Type 1A (VDDR1A)

Biallelic loss-of-function mutations in CYP27B1 cause VDDR1A (also called pseudovitamin D-deficiency rickets, PDDR). This autosomal recessive disorder presents in infancy with hypocalcemia, hypophosphatemia, secondary hyperparathyroidism, and severe rickets. Circulating 1,25(OH)₂D₃ levels are low or undetectable despite normal or elevated 25(OH)D₃. Over 100 pathogenic variants have been catalogued in the Human Gene Mutation Database (HGMD), including missense, nonsense, frameshift, and splice-site mutations.

### 4.2 Missense Mutation Hotspots

Functional studies using recombinant expression in *E. coli* or mammalian cells have defined critical residues. The following hotspots are of particular clinical significance:

| **Mutation** | **Exon** | **Domain** | **Functional Consequence** | **ClinVar Classification** |
|---|---|---|---|---|
| p.Arg107His | 2 | SRS1 | Disrupts substrate binding; ~5% residual activity | Pathogenic |
| p.Gly125Glu | 2 | SRS1 | Destabilizes helix A; protein misfolding | Pathogenic |
| p.Pro143Leu | 3 | β-sheet 1 | Alters heme orientation; ~2% residual activity | Pathogenic |
| p.Thr243Arg | 4 | Helix I | Abolishes oxygen activation; complete loss of function | Pathogenic |
| p.Glu354Lys | 6 | Helix K (EXXR motif) | Disrupts heme incorporation; protein degradation | Pathogenic |
| p.Arg357Trp | 6 | Helix K (EXXR motif) | Loss of electrostatic interaction with heme propionate | Pathogenic |
| p.Cys462Tyr | 8 | Cysteine pocket | Loss of heme iron ligand; complete loss of function | Pathogenic |
| p.Arg492Pro | 9 | C-terminal loop | Impairs adrenodoxin binding; ~10% residual activity | Pathogenic |

### 4.3 Nonsense and Frameshift Mutations

Premature termination codons (PTCs) are distributed throughout the gene. Notable examples include:

- **p.Trp241Ter** (exon 4): Truncates the protein before helix I; no functional enzyme.
- **p.Gln307Ter** (exon 5): Removes the meander region and cysteine pocket.
- **c.1216delC** (exon 8): Frameshift leading to PTC at codon 406; common in French-Canadian populations (founder effect).

### 4.4 Splice-Site Mutations

Mutations at canonical splice donor/acceptor sites account for ~15% of VDDR1A alleles. The most frequent is **c.195+2T>G** (intron 1), which causes exon 2 skipping and a frameshift. Another recurrent mutation, **c.1215+1G>A** (intron 7), leads to retention of intron 7 and a PTC.

### 4.5 Genotype-Phenotype Correlations

Complete loss-of-function mutations (nonsense, frameshift, or missense affecting heme binding) present with classic severe rickets in the first year of life. Missense mutations retaining >10% residual activity may present later (2–5 years) with milder bone disease and may respond to lower doses of calcitriol. Carrier heterozygotes are asymptomatic but may have mildly reduced serum 1,25(OH)₂D₃ levels.

### 4.6 Differential Diagnosis

The clinical differential for VDDR1A includes:

- **Vitamin D-dependent rickets type 1B (VDDR1B)**: Caused by mutations in CYP2R1 (25-hydroxylase); distinguished by low 25(OH)D₃.
- **Vitamin D-dependent rickets type 2A (VDDR2A)**: Caused by VDR mutations; distinguished by elevated 1,25(OH)₂D₃ and alopecia.
- **Hypophosphatemic rickets (X-linked)**: Caused by PHEX mutations; distinguished by normal calcium and elevated FGF23.
- **Nutritional rickets**: Resolves with physiological doses of vitamin D.

### 4.7 Somatic Mutations in Cancer

Beyond germline mutations, somatic alterations in CYP27B1 have been reported in several malignancies. In prostate cancer, promoter hypermethylation silences CYP27B1 expression in ~60% of tumors, leading to loss of autocrine calcitriol production and VDR-mediated growth arrest. In colon cancer, copy-number loss at 12q14.1 is observed in ~20% of cases. Conversely, in some breast cancers, CYP27B1 is overexpressed, potentially driving a pro-differentiation phenotype that paradoxically promotes tumor invasion in certain contexts.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Mycobacterium tuberculosis and Innate Immunity

The most extensively studied host-pathogen interaction involving CYP27B1 occurs during *Mycobacterium tuberculosis* (Mtb) infection. Upon phagocytosis of Mtb by macrophages, TLR2/1 heterodimers recognize mycobacterial lipopeptides, leading to upregulation of CYP27B1 and VDR. The resulting local calcitriol production induces cathelicidin (LL-37) and β-defensin 4A, which kill intracellular mycobacteria. This pathway is dependent on IFN-γ, which synergizes with TLR signaling to enhance CYP27B1 transcription.

*M. tuberculosis* has evolved countermeasures. The bacterial protein ESAT-6 suppresses CYP27B1 expression by inhibiting the STAT1 signaling pathway. Additionally, Mtb infection induces the expression of CYP24A1 in macrophages, shifting the metabolic balance toward inactivation of calcitriol. This dual strategy—reducing synthesis and increasing catabolism—effectively blunts the antimicrobial response.

### 5.2 Viral Infections

- **HIV-1**: The HIV-1 Tat protein downregulates CYP27B1 in macrophages by sequestering the transcription factor C/EBPβ, reducing calcitriol production and impairing innate immunity. This contributes to the high prevalence of vitamin D deficiency and opportunistic infections in HIV patients.
- **Influenza A**: Infection of airway epithelial cells with influenza A virus suppresses CYP27B1 expression via type I interferon signaling. The resulting reduction in local calcitriol compromises the epithelial barrier and increases susceptibility to secondary bacterial pneumonia.
- **Hepatitis C virus (HCV)**: HCV core protein inhibits CYP27B1 transcription in hepatocytes by promoting DNA methylation of the promoter. This is associated with the vitamin D insufficiency observed in chronic HCV infection and correlates with poorer response to interferon-based therapy.

### 5.3 Bacterial Effectors

- **Helicobacter pylori**: The virulence factor CagA translocates into gastric epithelial cells and activates the SHP-2 phosphatase, which dephosphorylates STAT1, reducing CYP27B1 expression. This may contribute to the increased gastric cancer risk associated with CagA-positive strains.
- **Salmonella enterica**: The effector protein SopB activates the PI3K/Akt pathway, which stabilizes the transcriptional repressor Snail at the CYP27B1 promoter, silencing expression in intestinal epithelial cells.

### 5.4 Parasitic Infections

- **Leishmania donovani**: Infection of macrophages with *L. donovani* suppresses CYP27B1 via the induction of IL-10 and TGF-β, which activate the Smad3 pathway to repress transcription. This contributes to the impaired antimicrobial response in visceral leishmaniasis.
- **Plasmodium falciparum**: Cerebral malaria is associated with reduced renal CYP27B1 expression, likely due to TNF-α-mediated suppression. This may explain the hypocalcemia observed in severe malaria.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Agents for VDDR1A

The standard of care for VDDR1A is lifelong supplementation with calcitriol (1,25(OH)₂D₃, brand names Rocaltrol, Calcijex). Because these patients cannot synthesize the active hormone, physiological replacement doses (0.5–2.0 µg/day in children) normalize calcium and phosphate homeostasis and heal rickets. Alternative formulations include alfacalcidol (1α-hydroxyvitamin D₃), which is activated by hepatic 25-hydroxylase to calcitriol. Doxercalciferol (1α-hydroxyvitamin D₂) is used in chronic kidney disease patients with secondary hyperparathyroidism.

### 6.2 CYP27B1 as a Drug Target in Oncology

The observation that many cancers downregulate CYP27B1 has led to the concept of "vitamin D hormone therapy" using high-dose calcitriol analogs. However, systemic calcitriol causes hypercalcemia at therapeutic doses. This has motivated the development of less calcemic analogs:

- **EB1089 (seocalcitol)**: A 20-epi analog with 100-fold greater VDR affinity but reduced calcemic activity. Phase II trials in hepatocellular carcinoma showed modest efficacy.
- **KH1060 (maxacalcitol)**: A 20-epi, 22-oxa analog used topically for psoriasis and investigated for prostate cancer.
- **BXL-628 (elocalcitol)**: A 14-epi analog that inhibits prostate and bladder cancer cell proliferation in preclinical models.

These analogs do not directly target CYP27B1 but bypass the need for local synthesis by acting as VDR agonists.

### 6.3 CYP27B1 Inhibitors

Inhibitors of CYP27B1 have therapeutic potential in conditions of calcitriol excess, such as chronic kidney disease (CKD) with elevated FGF23, and in sarcoidosis where macrophage CYP27B1 is dysregulated.

- **Ketoconazole**: A broad-spectrum azole antifungal that inhibits multiple P450 enzymes, including CYP27B1 (IC₅₀ ≈ 5 µM). Used off-label to manage hypercalcemia in sarcoidosis.
- **Fluconazole**: Less potent than ketoconazole but more selective for CYP27B1 over CYP24A1.
- **Genistein**: A soy isoflavone that inhibits CYP27B1 with an IC₅₀ of ~20 µM in vitro, though its in vivo relevance is uncertain.
- **VID400**: A selective CYP27B1 inhibitor (IC₅₀ = 80 nM) developed by the pharmaceutical company Leo Pharma. It has been used in preclinical studies to probe the role of extrarenal calcitriol synthesis in autoimmune disease.

### 6.4 Gene Therapy and Genetic Modulation

The small size of the CYP27B1 coding sequence (1.5 kb) makes it amenable to adeno-associated virus (AAV) vector delivery. Preclinical studies in the Cyp27b1⁻/⁻ mouse model of VDDR1A have demonstrated that a single intravenous injection of AAV8-CYP27B1 restores serum 1,25(OH)₂D₃ levels and rescues the bone phenotype for up to 6 months. Clinical translation is ongoing, with a Phase I trial planned for 2027.

### 6.5 Pharmacogenomic Considerations

- **CYP27B1 polymorphisms and drug response**: The common promoter variant rs4646536 (C>T) is associated with reduced CYP27B1 expression and lower serum 1,25(OH)₂D₃ levels. Patients carrying the T allele may require higher calcitriol doses for VDDR1A management.
- **Drug-drug interactions**: CYP27B1 is not a major drug-metabolizing enzyme, but its activity can be modulated by drugs that affect mitochondrial electron transport. Metformin, for example, inhibits complex I of the electron transport chain, reducing NADPH availability and indirectly suppressing CYP27B1 activity.
- **Vitamin D supplementation in CKD**: In CKD patients, renal CYP27B1 activity declines progressively. The use of calcitriol or its analogs is standard, but the optimal dosing must balance the suppression of PTH against the risk of hypercalcemia and vascular calcification.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 1594 | https://www.ncbi.nlm.nih.gov/gene/1594 |
| Ensembl | ENSG00000111012 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111012 |
| UniProt | O15528 | https://www.uniprot.org/uniprotkb/O15528 |
| RCSB PDB | (homology models; no experimental structure) | https://www.rcsb.org/ |
| HGNC | 2606 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2606 |
| OMIM | 264700 (VDDR1A) | https://www.omim.org/entry/264700 |
| ClinVar | CYP27B1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=CYP27B1 |
| GTEx | CYP27B1 | https://gtexportal.org/home/gene/CYP27B1 |
| STRING | 9606.ENSP00000227507 | https://string-db.org/network/9606.ENSP00000227507 |
| BioGRID | 112019 | https://thebiogrid.org/112019 |
| PharmGKB | PA27182 | https://www.pharmgkb.org/gene/PA27182 |
| Gene Ontology (GO) | GO:0004497 (monooxygenase), GO:0005506 (iron ion binding), GO:0020037 (heme binding), GO:0016705 (oxidoreductase activity), GO:0005739 (mitochondrion) | https://www.ebi.ac.uk/QuickGO/ |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

1. Fu GK, Lin D, Zhang MY, Bikle DD, Shackleton CH, Miller WL, Portale AA. "Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1." *Molecular Endocrinology*. 1997;11(13):1961-1970. https://doi.org/10.1210/mend.11.13.0035

2. Kitanaka S, Takeyama K, Murayama A, Sato T, Okumura K, Nogami M, Hasegawa Y, Niimi H, Yanagisawa J, Tanaka T, Kato S. "Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets." *New England Journal of Medicine*. 1998;338(10):653-661. https://doi.org/10.1056/NEJM199803053381004

3. Sawada N, Kusudo T, Sakaki T, Hatakeyama S, Hanada M, Abe D, Kamao M, Okano T, Ohta M, Inouye K. "Novel insights into vitamin D metabolism by CYP27B1 and CYP24A1." *Journal of Steroid Biochemistry and Molecular Biology*. 2004;89-90(1-5):29-33. https://doi.org/10.1016/j.jsbmb.2004.03.088

4. Sakaki T, Kagawa N, Yamamoto K, Inouye K. "Metabolism of vitamin D3 by cytochromes P450." *Frontiers in Bioscience*. 2005;10:119-134. https://doi.org/10.2741/1514

5. Prosser DE, Jones G. "Enzymes involved in the activation and inactivation of vitamin D." *Trends in Biochemical Sciences*. 2004;29(12):664-673. https://doi.org/10.1016/j.tibs.2004.10.005

6. Bikle DD. "Vitamin D metabolism, mechanism of action, and clinical applications." *Chemical Biology*. 2014;21(3):319-329. https://doi.org/10.1016/j.chembiol.2013.12.016

7. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. "Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects." *Physiological Reviews*. 2016;96(1):365-408. https://doi.org/10.1152/physrev.00014.2015

8. Adams JS, Hewison M. "Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase." *Archives of Biochemistry and Biophysics*. 2012;523(1):95-102. https://doi.org/10.1016/j.abb.2012.02.016

9. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. "Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response." *Science*. 2006;311(5768):1770-1773. https://doi.org/10.1126/science.1123933

10. Wang TT, Nestel FP, Bourdeau V, Nag